An international ban on players from the 12 clubs who announced on Sunday they would join a breakaway European Super League would result in wiping out nearly the entire squads of the England and Spain national teams, a Reuters analysis of club rosters shows. Europe's soccer governing body UEFA had warned players they could be denied the opportunity to play for their national teams if they compete in the breakaway competition that has drawn the ire of several clubs, leagues and national associations. England's big six -- Manchester United, Manchester City, Liverpool, Chelsea, Tottenham Hotspur and Arsenal -- and Spain's top three of Real Madrid, Barcelona and Atletico Madrid supply an overwhelming majority of players to both national teams.
Reporters Without Borders (RSF) ranked China fourth to last out of 180 countries on its 2021 World Press Freedom Index on Tuesday, while warning that Hong Kong journalism is also now under “grave threat.” China ranked 177th in 2019, 2020 and 2021, down from a period at 176th from 2015 to 2018. It currently rates […]
Speaking today are Richard J. Tobin, President and Chief Executive Officer; Brad Cerepak, Senior Vice President and Chief Financial Officer; and Andrey Galiuk, Vice President of Corporate Development and Investor Relations. Dover provides non-GAAP information and the reconciliations between GAAP and adjusted measures are included in our investor supplement and presentation materials, which are available on our website.
Infielder Neil Walker announced his retirement Tuesday at age 35 after 12 major league seasons. Walker hit .231 with no homers and three RBIs in 18 games with Philadelphia this year. Walker hit .267 with 149 homers and 60 RBIs for Pittsburgh, the New York Mets, Milwaukee, Philadelphia, Miami and the New York Yankees.
PGT Innovations, Inc. (NYSE:PGTI) will release its financial results and host a conference call on Thursday, May 13, 2021, to discuss the company's first quarter 2021 results as well as other business matters. The teleconference will begin at 10:30 a.m. eastern time and will be hosted by Jeff Jackson, President and Chief Executive Officer, and Brad West, Senior Vice President and Interim Chief Financial Officer. The company's press release announcing the financial results will be issued pre-market at approximately 7:30 a.m. on May 13th and will also be available through the Investors section of the PGT Innovations, Inc. website: http://ir.pgtinnovations.com/releases.cfm.
Josh Miller walked away from the U.S. capital's convention center on Tuesday with a COVID-19 vaccination and a joint. He was among the Washingtonians who took advantage of "Joints for Jabs," a weed giveaway by a local advocacy organization to encourage residents to get vaccinated and lobby their council members to reform the city's marijuana laws. "I'm here for multiple reasons," Miller said outside the Walter E. Washington Convention Center after collecting a tube containing a tightly rolled joint.
Saint-Herblain (France), April 20, 2021 – Valneva SE, a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need, today announced it is now focusing on bilateral discussions, on a country by country basis, to supply its inactivated, adjuvanted COVID-19 vaccine candidate, VLA2001, and is consequently deprioritizing the ongoing centralized discussions with the European Commission (EC). This follows the recent announcement on April 6, 2021 of positive initial results from the Phase 1/2 clinical trial of VLA20011. Valneva previously announced the advanced stage of its discussions, which started in the third quarter of 2020, with the EC on January 12, 20212. In September 2020, Valneva announced a collaboration with the UK government to provide up to 190 million doses of VLA2001 through 20253, of which 100 million doses have already been ordered. Thomas Lingelbach, Chief Executive Officer of Valneva, said, “We’ve committed significant time and effort to try to meet the needs of the central EC procurement process. Despite our recent clinical data, we have not made meaningful progress and have not yet secured a supply agreement. We are therefore now focusing our efforts on those European Union member states, and interested parties outside the EU, who would like to include our inactivated approach within their vaccination strategy. We are convinced that VLA2001 has an important role to play in the future, including boosters or potential modifications to the vaccine to address variants”. Valneva has the only inactivated vaccine candidate in clinical trials against COVID-19 in Europe and is preparing a pivotal, comparative immunogenicity Phase 3 clinical trial expected to commence by the end of April 2021 with the aim of making regulatory licensure submissions in the autumn of 2021. About the Novel Coronavirus SARS-CoV-2 and COVID-19 DiseaseSARS-CoV-2 is a new coronavirus identified in late 2019 and belongs to a family of enveloped RNA viruses that include MERS and SARS, both of which caused serious human infections of the respiratory system. The virus, which causes a disease named COVID-19, has never before been found in humans. Since this outbreak was first reported, the virus has caused millions of deaths globally4. It has been declared a pandemic by the World Health Organization (WHO). About VLA2001VLA2001 is currently the only whole virus, inactivated, adjuvanted vaccine candidate in clinical trials against COVID-19 in Europe. It is intended for active immunization of at-risk populations to prevent carriage and symptomatic infection with COVID-19 during the ongoing pandemic and potentially later for routine vaccination including addressing new variants. VLA2001 may also be suited for boosting, as repeat booster vaccinations have been shown to work well with whole virus inactivated vaccines. VLA2001 is produced on Valneva’s established Vero-cell platform, leveraging the manufacturing technology for Valneva’s licensed Japanese encephalitis vaccine, IXIARO®. VLA2001 consists of inactivated whole virus particles of SARS-CoV-2 with high S-protein density, in combination with two adjuvants, alum and CpG 1018. This adjuvant combination has consistently induced higher antibody levels in preclinical experiments than alum-only formulations and shown a shift of the immune response towards Th1. CpG 1018 adjuvant, supplied by Dynavax Technologies Corporation (Nasdaq: DVAX), is a component of the US FDA- and EMA-approved HEPLISAV-B® vaccine. The manufacturing process for VLA2001, which has already been upscaled to final industrial scale, includes inactivation with BPL to preserve the native structure of the S-protein. VLA2001 is expected to conform with standard cold chain requirements (2 degrees to 8 degrees Celsius). About Valneva SEValneva is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need. We take a highly specialized and targeted approach to vaccine development, beginning with the identification of deadly and debilitating infectious diseases that lack a prophylactic vaccine solution and for which there are limited therapeutic treatment options. We then apply our deep understanding of vaccine science, including our expertise across multiple vaccine modalities, as well as our established vaccine development capabilities, to develop prophylactic vaccines to address these diseases. We have leveraged our expertise and capabilities both to successfully commercialize two vaccines and to rapidly advance a broad range of vaccine candidates into and through the clinic, including candidates against Lyme disease, the chikungunya virus and COVID-19. Valneva Investor and Media ContactsLaetitia Bachelot-FontaineDirector Investor Relations & Corporate CommunicationsM +33 (0)6 4516 email@example.com Dan SharpGovernment & Public Affairs Manager T +44-(0)firstname.lastname@example.org Valneva Forward-Looking StatementsThis press release contains certain forward-looking statements relating to the business of Valneva, including with respect to the progress, timing, results and completion of research, development and clinical trials for product candidates, timing and volume expectations with respect to the manufacture of our product candidates; the ability to market, commercialize and achieve market acceptance for product candidates, the ability to protect intellectual property and operate the business without infringing on the intellectual property rights of others, estimates for future performance and estimates regarding anticipated operating losses, future revenues, capital requirements and needs for additional financing. In addition, even if the actual results or development of Valneva are consistent with the forward-looking statements contained in this press release, those results or developments of Valneva may not be sustained in the future. In some cases, you can identify forward-looking statements by words such as "could," "should," "may," "expects," "anticipates," "believes," "intends," "estimates," "aims," "targets," or similar words. These forward-looking statements are based largely on the current expectations of Valneva as of the date of this press release and are subject to a number of known and unknown risks and uncertainties and other factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievement expressed or implied by these forward-looking statements. In particular, the expectations of Valneva could be affected by, among other things, uncertainties involved in the development and manufacture of vaccines, unexpected clinical trial results, unexpected regulatory actions or delays, competition in general, currency fluctuations, the impact of the global and European credit crisis, and the ability to obtain or maintain patent or other proprietary intellectual property protection. Success in preclinical studies or earlier clinical trials may not be indicative of results in future clinical trials. In light of these risks and uncertainties, there can be no assurance that the forward-looking statements made during this presentation will in fact be realized. Valneva is providing the information in these materials as of this press release, and disclaim any intention or obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. 1 Valneva Reports Positive Phase 1/2 Data for Its Inactivated, Adjuvanted COVID-19 Vaccine Candidate, VLA20012 Valneva in Advanced Discussions with European Commission to Supply up to 60 Million Doses of Inactivated, Adjuvanted COVID-19 Vaccine Candidate3 Valneva Announces Major COVID-19 Vaccine Partnership with U.K. Government4 https://www.worldometers.info/coronavirus/ Attachment 2021_04_20_VLA2001_EC_PR_EN_Final
Nathan Aspinall and Michael Van Gerwen, who began the night level on points with Van Den Bergh at the top, drew their respective matches.
United Airlines Holdings (NASDAQ: UAL) provided a tepid outlook for the next few months, putting the entire sector under pressure. Shares of United traded down by as much as 10% on Tuesday, and American Airlines Group (NASDAQ: AAL), Delta Air Lines (NYSE: DAL), JetBlue Airways (NASDAQ: JBLU), and Spirit Airlines (NYSE: SAVE) all fell, as well.
President Joe Biden and Vice President Kamala Harris will deliver remarks on the trial of Derek Chauvin, the former Minneapolis police officer who was found guilty in the death of George Floyd. The president and the vice president watched the verdict with staff in the private dining room, according to a report by a pool of reporters. Following the announcement of the verdict, Biden spoke with Minnesota Gov. Tim Walz.
Rickie Fowler was eligible to play in every major dating to the 2010 British Open at St. Andrews, a streak that ended at the Masters when he fell out of the top 50 in the world. Jason Day could be next in line for major streaks being in jeopardy. Day has a lifetime exemption to the PGA Championship, which is May 20-23 at Kiawah Island, from his 2015 victory at Whistling Straits.
President Joe Biden and Vice President Kamala Harris called the family of George Floyd following the announcement of a guilty verdict against former Minneapolis police officer Derek Chauvin. Biden could be heard saying on the call, “Feeling better now. Nothing is going to make it all better, but at least there is some justice.” Ben […]
He commended Manchester City and Chelsea for dropping out
Chauvin showed no emotion as he was convicted on all three murder charges
Kevin Stefanski isn't necessarily proud that he and his coaching staff have become proficient at working virtually. The Browns had their second day of remote meetings Tuesday after Cleveland's players — along with more than a dozen teams across the NFL — decided to skip any voluntary in-person workouts for the time being because of the COVID-19 pandemic. Stefanski managed to maneuver around all kinds of obstacles in his first season with Cleveland.
Follow the latest as Chelsea and Manchester City lead a breakdown of the plans to form a breakaway European league
Derek Chauvin may have been found guilty of murder, but the people of Minneapolis say true justice is much bigger than one court decision
The new competition looks doomed just 48 hours after it was announced.
Byron Thanarayen and his wife Melissa are hugging their pups tight after their toy Pomeranian Chucky nearly drowned in their pool last week
Climbdown comes after defeat in House of Lords over provisions of bill to protect troops from false prosecution